CLEOCIN PHOSPHATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLEOCIN PHOSPHATE (CLEOCIN PHOSPHATE).
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. Clindamycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. It exhibits bacteriostatic activity against susceptible bacteria.
| Metabolism | Clindamycin is metabolized primarily in the liver via CYP3A4 to active and inactive metabolites. The phosphate ester is hydrolyzed to clindamycin. Approximately 10% is excreted unchanged in urine, with the remainder as metabolites. |
| Excretion | Approximately 10% as active drug and metabolites in urine, 3.6% in feces; major route is hepatic metabolism to inactive metabolites (N-demethylclindamycin and clindamycin sulfoxide) excreted in bile and feces. Renal excretion accounts for about 10% of the dose, with the remainder eliminated via biliary/fecal route. |
| Half-life | Terminal elimination half-life is 2-3 hours in adults with normal renal and hepatic function; may be prolonged to 4-5 hours in patients with severe hepatic impairment (Child-Pugh C). In neonates, half-life ranges from 8-12 hours, decreasing to adult values by 1 month of age. |
| Protein binding | Approximately 92-94% bound primarily to albumin, with minor binding to α1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.6-1.2 L/kg (mean 0.9 L/kg) indicating extensive tissue distribution; concentrates in bone, bile, and skin/soft tissues; crosses placenta and blood-brain barrier poorly except with inflamed meninges. |
| Bioavailability | Oral (CLEOCIN HCL capsules): 87-90% bioavailability; Intramuscular: approximately 100% bioavailability relative to IV; Topical (CLEOCIN T gel/lotion/solution): minimal systemic absorption (approximately 1-2%); Vaginal cream: approximately 5% systemic absorption. |
| Onset of Action | Intravenous: Immediate upon completion of infusion; Intramuscular: 1-2 hours; Oral: 1-2 hours (for CLEOCIN HCL); Topical (CLEOCIN T): 12-24 hours for visible reduction of acne lesions; Vaginal cream: 12-24 hours for symptomatic relief of bacterial vaginosis. |
| Duration of Action | Therapeutic effect duration: 6-8 hours for systemic infections with IV/IM dosing; oral dosing maintains levels for approximately 6 hours; topical/vaginal formulations provide local effect for 24 hours with once-daily dosing. Clinical duration depends on MIC of pathogen and dose. |
600-2700 mg/day IV/IM in 2-4 divided doses. Typical: 600-900 mg IV q8h or 300-600 mg IM q12h.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR >30 mL/min. For GFR <30 mL/min, no adjustment needed but monitor for accumulation with prolonged use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or avoid use. |
| Pediatric use | Neonates (≥7 days): 15-20 mg/kg/day IV/IM divided q6-8h. Infants and children (≥1 month): 20-40 mg/kg/day IV/IM divided q6-8h. Maximum 2700 mg/day. |
| Geriatric use | No specific dose adjustment, but consider age-related renal and hepatic function decline; monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLEOCIN PHOSPHATE (CLEOCIN PHOSPHATE).
| Breastfeeding | Clindamycin is excreted in human breast milk in low concentrations (M/P ratio approximately 0.1-0.5). The American Academy of Pediatrics considers it compatible with breastfeeding. Monitor infant for diarrhea, rash, or alterations in gut flora. |
| Teratogenic Risk | Clindamycin phosphate (Cleocin Phosphate) is classified as FDA Pregnancy Category B. Animal studies do not indicate fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No reported teratogenicity; crosses placenta. Second and third trimesters: Considered safe for short-term use; no known fetal harm. |
■ FDA Black Box Warning
Clindamycin can cause severe colitis and pseudomembranous colitis, which may be fatal. Clostridium difficile-associated diarrhea (CDAD) has been reported. If colitis occurs, discontinue clindamycin.
| Serious Effects |
Hypersensitivity to clindamycin, lincomycin, or any component of the formulation. History of clindamycin- or lincomycin-associated colitis. Use in meningitis (due to inadequate CSF penetration). Caution in neuromuscular disorders (may exacerbate neuromuscular blockade).
| Precautions | Clostridium difficile-associated diarrhea (CDAD) can occur even weeks after discontinuation. Monitor for signs of colitis. Use caution in patients with gastrointestinal disease, hepatic impairment, or renal impairment. May cause severe hypersensitivity reactions including anaphylaxis. Prolonged use may result in superinfection. |
| Food/Dietary | Food does not significantly affect the absorption of oral clindamycin, but may reduce gastrointestinal adverse effects. No specific dietary restrictions. Avoid alcohol due to potential for increased gastrointestinal irritation. |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function, renal function, and complete blood count during prolonged therapy. Assess for signs of pseudomembranous colitis. Fetal monitoring not required unless high maternal dose or prolonged exposure. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data available; unlikely to impair fertility at therapeutic doses. |
| Clinical Pearls | Cleocin Phosphate (clindamycin phosphate) is a lincosamide antibiotic that inhibits bacterial protein synthesis. For intravenous administration, avoid rapid bolus; infuse over at least 10-60 minutes to reduce risk of hypotension and cardiac arrest. Monitor for pseudomembranous colitis due to C. difficile, which can occur even weeks after discontinuation. May prolong neuromuscular blockade; use with caution in patients receiving neuromuscular blocking agents. Clindamycin has excellent bone penetration, making it useful for osteomyelitis. In topical form, it is often combined with benzoyl peroxide for acne. |
| Patient Advice | Complete the full course of this antibiotic even if you feel better. · Diarrhea, especially watery or bloody, may occur during or after treatment; contact your doctor immediately. · Avoid alcohol while taking this medication as it may increase the risk of stomach upset. · Notify your doctor if you have a history of colitis, kidney disease, or liver disease. · For topical use: wash affected area before application; avoid contact with eyes and mucous membranes. · This medication may cause a metallic or unpleasant taste in the mouth. · Do not use this medication for infections other than those for which it was prescribed. |